Sorry!! The article you are trying to read is not available now.
November 12, 2012 at 09:16 AM EST
Gilead Shares Rise on Hepatitis C Treatment
MINYANVILLE ORIGINAL Shares of Gilead Sciences (NASDAQ:GILD) are rising after the drug maker said a combination of its therapies were 100% effective in curing a small group of previously untreated patients for hepatitis C. The finding and other data will be presented at a medical meeting in Boston this week. Abbott Laboratories (NYSE:ABT) showed that it is neck and neck with Gilead in the race for a better hepatitis C therapy by announcing its own impressive results over the weekend. Abbott said it cured 97.5% of patients who had not previously been treated with any drugs for the liver-wasting ...
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here

WHAT'S POPULAR IN THE VILLE